A5032953745- Helicobacter pylori-related gastroenterology studies
- Gastroesophageal reflux and treatments
- Potassium and Related Disorders
- Neuroendocrine Tumor Research Advances
- Calcium signaling and nucleotide metabolism
- Adenosine and Purinergic Signaling
- Gastrointestinal motility and disorders
- Pharmacological Receptor Mechanisms and Effects
Korea Innotech (South Korea)
2021-2024
Aims Nocturnal acid breakthrough has been considered an unmet need of proton‐pump inhibitors. Tegoprazan, a novel potassium‐competitive blocker, is expected to show improved properties for this need. This study was aimed compare night‐time suppression by tegoprazan with that vonoprazan or esomeprazole, and explore the effect CYP2C19 phenotypes on acid‐suppressive effects. Methods A randomized, open‐label, 3‐period, 6‐sequence crossover conducted. single oral dose 50 mg, 20 mg esomeprazole 40...
Sungpil Han, Hee Youn Choi, Yo Han Kim, SeungChan Seokuee Ji Yeon Nam, Bongtae Geun Seog Song, Hyeong-Seok Lim, and Kyun-Seop Bae. Gut Liver 2023;17:92-9. https://doi.org/10.5009/gnl220050
Building on the preceding structural analysis and a structure–activity relationship (SAR) of 8-aryl-2-hexynyl nucleoside hA2AAR antagonist 2a, we strategically inverted C2/C8 substituents eliminated ribose moiety. These modifications aimed to mitigate potential steric interactions between adenosine receptors. The SAR findings indicated that such inversions significantly modulated hA3AR binding affinities depending type ribose, whereas removal altered functional efficacy via hA2AAR. Among...
Tegoprazan is a potassium-competitive acid blocker used for gastric suppression, which may be with Helicobacter pylori eradication therapies. The goal of this study was to evaluate the pharmacokinetic interaction between tegoprazan and triple-antibiotic therapy containing metronidazole, tetracycline, bismuth.An open-label, 2-cohort, randomized, multiple-dose, crossover conducted in healthy subjects. In cohort 1, (100 mg/d) administered orally or without (1500 mg/d 2000 1200 bismuth) 7 days...
Tegoprazan is a novel potassium-competitive acid blocker that treats gastric acid-related diseases. Clarithromycin was widely used as one of various regimens for eradicating Helicobacter pylori. This study compared the pharmacokinetic and safety profile tegoprazan clarithromycin between combination therapy monotherapy to evaluate potential drug-drug interaction. An open-label, randomized, 6-sequence, 3-period crossover conducted in 24 healthy subjects. According assigned sequence, subject...
Potassium-competitive acid blocker is a new class of drugs inhibiting gastric acid. It controversial that vonoprazan showed the inhibitory activities cytochrome P450 3A4. This study aimed to evaluate pharmacokinetics (PK) atorvastatin and safety when was administered alone co-administered with or tegoprazan. An open-label, multiple-dose, 3-intervention, 4-sequence, 4-period, partial replicate crossover conducted, three interventions were; one orally 40 mg once daily for 7 days, another 20...